Cytokines

Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial

Retrieved on: 
Friday, April 30, 2021

A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.

Key Points: 
  • A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.
  • In parallel with the Phase III trial in the hospital setting, there is now an urgent need to assess SNG001 in the non-hospital setting, focussing entirely on breathless COVID-19 patients.
  • Please find a link to this webcast here.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No.
  • 596/2014 (\xe2\x80\x98MAR\xe2\x80\x99).\nThe Lancet Respiratory Medicine: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial".

AmMax Bio to Present at the BofA Securities 2021 Virtual Healthcare Conference

Retrieved on: 
Thursday, April 29, 2021

b'REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (\xe2\x80\x9cAmMax\xe2\x80\x9d), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will present at the BofA Securities 2021 Virtual Healthcare Conference.

Key Points: 
  • b'REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (\xe2\x80\x9cAmMax\xe2\x80\x9d), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will present at the BofA Securities 2021 Virtual Healthcare Conference.
  • A long-acting AMB-05X with strong anti-fibrotic activity will reduce patient treatment burden and is expected to limit vision loss from macular fibrosis.
  • Overactivation of the CSF1/IL-34 \xe2\x80\x93 CSF1R axis substantially contributes to the inflammation and fibrosis inherent in many diseases.
  • Thus, the potent inhibition of CSF1R activity by AMB-05X represents a novel and powerful means of therapeutic intervention via its dual action.\n'

INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference

Retrieved on: 
Monday, April 26, 2021

is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

Key Points: 
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases.
  • INmune Bio\xe2\x80\x99s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Hepatocyte Growth Factor Pipeline Report, H2 2020 Edition - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021

b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.

Key Points: 
  • b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.
  • It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing.
  • In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.\nThe report \'Hepatocyte Growth Factor - Pipeline Review, H2 2020\' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.\nIt also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.
  • Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 5, 3, 4 and 3 respectively.\nThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities\n'

Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting

Retrieved on: 
Wednesday, April 21, 2021

Sustained exposure to the distal regions of the lungs is an important consideration for the efficacious treatment of BOS.

Key Points: 
  • Sustained exposure to the distal regions of the lungs is an important consideration for the efficacious treatment of BOS.
  • Further, treatment via a handheld nebulizer may provide a convenient portable intervention option for lung transplant patients experiencing BOS.
  • ALTA-2530, a recombinant human IL-1Ra, binds competitively to the IL-1 receptor to attenuate the inflammatory response.
  • ALTA-2530 is a recombinant human interleukin-1 receptor antagonist under development for bronchiolitis obliterans syndrome (BOS), a life-threatening form of chronic lung allograft dysfunction (CLAD) that frequently presents following lung transplantation.

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)

Retrieved on: 
Friday, April 23, 2021

PASI 75 is defined as at least a 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) scores.

Key Points: 
  • PASI 75 is defined as at least a 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) scores.
  • In the same timeframe across both studies, EAIRs for AEs leading to discontinuation were 9.4 with placebo, 4.4 with deucravacitinib and 11.6 with Otezla.
  • Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-12, IL-23 and Type 1 interferon (IFN), key cytokines involved in psoriasis pathogenesis.
  • In addition to POETYK PSO-1 and POETYK PSO-2, Bristol Myers Squibb is evaluating deucravacitinib in three other Phase 3 studies in psoriasis: POETYK PSO-3 (NCT04167462); POETYK PSO-4 (NCT03924427); POETYK PSO-LTE (NCT04036435).

Organicell Completes Enrollment for its Expanded Access Trial to Treat COVID-19 Patients with Zofin™

Retrieved on: 
Thursday, April 22, 2021

Organicell is hoping to help patients that currently do not have an approved therapy.

Key Points: 
  • Organicell is hoping to help patients that currently do not have an approved therapy.
  • This product contains over 300 growth factors, cytokines, and chemokines as well as extracellular vesicles/nanoparticles derived from perinatal tissues.
  • Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210422005336/en/\n'

MyMD Pharmaceuticals Begins Trading on Nasdaq

Retrieved on: 
Monday, April 19, 2021

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.

Key Points: 
  • MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.
  • MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\xce\xb1 blocking drugs, and aging and longevity.
  • Forward-looking statements speak only as of the date they are made and none of MYMD nor its affiliates assume any duty to update forward-looking statements.
  • A discussion of these and other factors with respect to MYMD is set forth in the registration statement on Form S-4 filed by MYMD on January 15, 2021, as amended.

BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

Retrieved on: 
Thursday, April 1, 2021

Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.

Key Points: 
  • Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.
  • There is a large unmet medical need and a growing market for CIN prevention and treatment in China as well.
  • According to IQVIA data, the G-CSF drug market (for CIN treatment) in China is growing at over 30% a year.
  • Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies.

Global TNF Alpha Inhibitors Market Report 2020-2030: COVID-19 Growth and Change - Market is Expected to Decline from $40.66 Billion in 2019 to $39.01 Billion in 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 25, 2021

The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-) inhibitors by entities that manufacture TNF alpha inhibitors.
  • The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market.
  • Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion